Genertec Universal Medical : UNAUDITED OPERATION SUMMARY OF THE GROUP FOR THE FIRST QUARTER OF 2021

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GENERTEC UNIVERSAL MEDICAL GROUP COMPANY

LIMITED

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code：2666)

UNAUDITED OPERATION SUMMARY OF THE GROUP

FOR THE FIRST QUARTER OF 2021

This announcement sets out the unaudited operation summary of Genertec Universal Medical Group

Company Limited (the "Company"), together with its subsidiaries (the "Group"), for the first

quarter ended 31 March 2021.

This announcement is made pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules") and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

During the first quarter of 2021, under the new norm of Covid-19 epidemic control in China, the Company, together with its member medical institutions, was orderly engaged in its business development under the guidance of the Group's strategic plan and achieved a stable growth in operating results. For the three months ended 31 March 2021, the revenue of the Group increased by approximately 22% as compared with the corresponding period of 2020, and the profit for the period attributable to ordinary shareholders of the parent increased by approximately 42% as compared with the corresponding period of 2020, mainly due to significant impact from Covid-19 epidemic on the profit during the first quarter of the previous year.

In respect of finance and advisory business, with the continuous efforts of intensive and meticulous implementations in various regions, as compared with the end of 2020, interest-earning assets achieved a sustainable growth, while net interest margin and net interest spread both remained stable and assets quality remained in a good condition.

In respect of hospital group business, as at 31 March 2021, the Group had entered into contacts in relation to takeover of 56 medical institutions, of which 40 had been consolidated into financial statements with actual capacity up to approximately 10,200 beds. In the meanwhile, the Group

continued its efforts to improve the development of discipline constructions, operation management and service capabilities of the member medical institutions, enhancing their service quality, management efficiency and operating performance.

In respect of health industry business, focusing on core medical resources, the Group actively launched the expansion of layout in internet-based healthcare, equipment maintenance, medical testing, insurance and health and wellness business so as to complete the healthcare industry chain.

In respect of financing support, the Group actively took advantage of onshore and offshore financing instruments while ensuring its capital liquidity and prudent debt maturity structure. The average funding cost for the first quarter of this year remained stable as compared to that of 2020.

In addition, references are made to the announcements of the Company dated 23 May 2018, 4 June 2019, 5 March 2020 and 19 May 2020 in relation to the issuance of the medium-term notes with an aggregate principal amount of RMB2.5 billion in the inter-bank market in the People's Republic of China (the "PRC") by China Universal Leasing Co., Ltd. (中國環球租賃有限公司) ("Universal Leasing"), a wholly-owned subsidiary of the Company.

In accordance with the relevant laws and regulations of the PRC, the unaudited consolidated financial information of Universal Leasing for the three months ended 31 March 2021 (the "Universal Leasing Consolidated Financial Information") has been published on the websites of Shanghai Clearing House (www.shclearing.com) and China Foreign Exchange Trade System (www.chinamoney.com.cn) on 29 April 2021. The Company's board of directors would like to draw the attention of its shareholders and investors to the following principal financial data of Universal Leasing:

PRINCIPAL CONSOLIDATED FINANCIAL DATA OF UNIVERSAL LEASING

		Unit: Thousand Yuan
		Currency: RMB
	As at 31 March 2021	As at 31 December 2020
	(unaudited)	(audited)
Total assets	63,397,281	61,156,280
Total equity	16,461,042	15,778,168
	For the three months ended	For the three months ended
	31 March 2021	31 March 2020
	(unaudited)	(unaudited)
Operating income	2,317,444	1,890,891
Profit for the period	482,498	363,619
Net cash flows from / (used in)	4,529	(624,746)
operating activities

The Company hereby reminds investors that the above unaudited operation summary for the first quarter ended 31 March 2021 was prepared based on the Group's internal figures and management accounts which have not been reviewed or audited by the auditors of the Group. The Universal Leasing Consolidated Financial Information was prepared in accordance with the General Accepted Accounting Principles of the PRC, which may require adjustment during the course of auditing of the financial results of the Group, and the information contained therein is limited solely to the operation of Universal Leasing, which does not provide a full picture of the operation status of the Group or comparison with the Group.

Investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board

Genertec Universal Medical Group Company

Limited

通用環球醫療集團有限公司

Peng Jiahong

Executive Director

Beijing, PRC, 29 April 2021

As at the date of this announcement, the executive directors of the Company are Ms. Peng Jiahong (Vice-chairwoman) and Mr. Yu Gang; the non-executive directors of the Company are Mr. Zhang Yichen (Chairman), Ms. Liu Kun and Mr. Liu Zhiyong; and the independent non-executive directors of the Company are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Han Demin and Mr. Liao Xinbo.